|
gptkbp:instanceOf
|
gptkb:antiviral_drug
gptkb:drug
|
|
gptkbp:administeredBy
|
oral route
intravenous route
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J05AE03
|
|
gptkbp:bioavailability
|
75-80%
|
|
gptkbp:brand
|
gptkb:Norvir
|
|
gptkbp:CASNumber
|
gptkb:155213-67-5
|
|
gptkbp:category
|
gptkb:antiretroviral_therapy
gptkb:WHO_essential_medicine
CYP2D6 inhibitor
CYP3A inhibitor
|
|
gptkbp:chemicalFormula
|
peptidomimetic
|
|
gptkbp:combines
|
gptkb:lopinavir
gptkb:atazanavir
gptkb:darunavir
gptkb:tipranavir
saquinavir
|
|
gptkbp:contraindication
|
severe liver impairment
|
|
gptkbp:developedBy
|
gptkb:Abbott_Laboratories
|
|
gptkbp:discoveredIn
|
1996
|
|
gptkbp:drugClass
|
gptkb:protease_inhibitor
|
|
gptkbp:eliminationHalfLife
|
3-5 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstSynthesized
|
gptkb:Abbott_Laboratories
|
|
gptkbp:form
|
gptkb:tablet
capsule
oral solution
|
|
gptkbp:hasMolecularFormula
|
C37H48N6O5S2
|
|
gptkbp:inhibitedBy
|
gptkb:CYP2D6
gptkb:CYP3A4
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits HIV protease
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patent
|
gptkb:US_Patent_5484907
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
98-99%
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
gptkb:lipodystrophy
nausea
vomiting
diarrhea
liver toxicity
|
|
gptkbp:usedAs
|
pharmacokinetic enhancer
|
|
gptkbp:usedFor
|
HIV/AIDS treatment
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Zentiva
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ritonavir
|